One of them is CRISPR Therapeutics ( CRSP -0.90%). It has an approved gene-editing therapy, but investors haven't been buying ...

The company has shown its revolutionary technology can deliver life-changing therapies. Now, it's about whether CRISPR ...

Vertex Pharmaceuticals, best known for its breakthrough cystic fibrosis (CF) treatments, is to become one of the first partners of CRISPR Therapeutics, a leader in new gene-editing technology.

CRISPR Therapeutics partnered with big biotech Vertex Pharmaceuticals (NASDAQ: VRTX) on Casgevy. Although Vertex takes a larger share of profit at 60%, this is worthwhile because Vertex has the ...

CRISPR Therapeutics’ partner Vertex reported that more than 65 treatment centers have been activated for the gene therapy ...

CRISPR Therapeutics faces challenges with a 20% stock drop, slow Casgevy commercialization, and regulatory hurdles. Read more ...

Vertex Pharmaceuticals Incorporated’s VRTX first-quarter results were weak as it missed estimates for both earnings and sales ...

We expect Vertex Pharmaceuticals Incorporated VRTX to surpass expectations when it reports first-quarter 2025 results on May 5, after market close. The Zacks Consensus Estimate for the to-be-reported ...

was developed in collaboration with narrow-moat Vertex Pharmaceuticals to treat transfusion-dependent beta-thalassemia (TDT) and sickle-cell disease (SCD). Crispr Therapeutics and Vertex have ...

Vertex Pharmaceuticals is diversifying its already strong lineup of medicines. Axsome Therapeutics has multiple clinical and regulatory catalysts on the way. Two excellent candidates are Vertex ...

CRISPR Therapeutics has begun realizing sales on Casgevy, its first therapy and a joint venture with Vertex Pharmaceuticals. The company has plenty of cash to fund research and development for the ...

That's only about 6 times next year's revenue estimates, and sales should continue to grow, since CRISPR Therapeutics and Vertex Pharmaceuticals have just started rolling out Casgevy. Even better ...